Urogen Pharma's (URGN) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Urogen Pharma (NASDAQ:URGN - Free Report) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $50.00 price objective on the stock.

Several other research firms have also weighed in on URGN. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Urogen Pharma in a research note on Monday. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the company a "buy" rating in a research note on Friday, June 13th. Guggenheim reissued a "buy" rating and set a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the company a "neutral" rating in a research note on Friday, June 13th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $32.86.

Urogen Pharma Price Performance

NASDAQ:URGN traded down $0.40 during trading hours on Tuesday, hitting $14.24. The company's stock had a trading volume of 725,369 shares, compared to its average volume of 1,091,733. The stock has a fifty day simple moving average of $9.94 and a 200-day simple moving average of $10.36. The company has a market capitalization of $656.61 million, a P/E ratio of -4.48 and a beta of 1.02. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $18.15.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. On average, equities analysts predict that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Activity

In other news, insider Mark Schoenberg sold 5,162 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the sale, the insider directly owned 153,378 shares in the company, valued at $1,130,395.86. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 5.10% of the company's stock.

Hedge Funds Weigh In On Urogen Pharma

Institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC lifted its position in shares of Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after acquiring an additional 5,140 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Urogen Pharma in the fourth quarter valued at $59,000. Lazard Asset Management LLC acquired a new position in shares of Urogen Pharma during the fourth quarter valued at about $67,000. GAMMA Investing LLC boosted its position in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after purchasing an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Urogen Pharma in the 4th quarter valued at about $101,000. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.